Abstract：
UNASSIGNED: This survey assessed psychiatry residents\'/early-career psychiatrists\' attitudes towards the utility of therapeutic drug monitoring (TDM) of antipsychotics.
UNASSIGNED: A previously developed questionnaire on attitudes on TDM utility during antipsychotic treatment was cross-sectionally disseminated by national coordinators between 01/01/2022-31/12/2023. The frequency of using TDM for antipsychotics other than clozapine was the main outcome in a linear regression analysis, including sex, clinical setting, caseload, and factors generated by an exploratory factor analysis. Comparisons between residents and early-career psychiatrists, respondents working in in- and outpatient settings, and low-/middle- and high-income countries were performed.
UNASSIGNED: Altogether, 1,237 respondents completed the survey, with 37.9% having never used TDM for antipsychotics. Seven factors explained 41% of response variance; six of them were associated with frequency of TDM use (p < 0.05). Items with highest loadings for factors included clinical benefits of TDM (factors A and E: 0.7), negative expectations for beliefs of patients towards TDM (factor B: 0.6-0.7), weak TDM scientific evidence (factor C: 0.8), and TDM availability (factor D: -0.8). Respondents from low-/middle-income countries were less likely to frequently/almost always use TDM compared to high-income countries (9.4% vs. 21.5%, p < 0.001).
UNASSIGNED: TDM use for antipsychotics was poor and associated with limited knowledge and insufficient availability.
UNASSIGNED: A previously developed questionnaire on attitudes on TDM utility during antipsychotic treatment was cross-sectionally disseminated by national coordinators between 01/01/2022-31/12/2023. The frequency of using TDM for antipsychotics other than clozapine was the main outcome in a linear regression analysis, including sex, clinical setting, caseload, and factors generated by an exploratory factor analysis. Comparisons between residents and early-career psychiatrists, respondents working in in- and outpatient settings, and low-/middle- and high-income countries were performed.
UNASSIGNED: Altogether, 1,237 respondents completed the survey, with 37.9% having never used TDM for antipsychotics. Seven factors explained 41% of response variance; six of them were associated with frequency of TDM use (p < 0.05). Items with highest loadings for factors included clinical benefits of TDM (factors A and E: 0.7), negative expectations for beliefs of patients towards TDM (factor B: 0.6-0.7), weak TDM scientific evidence (factor C: 0.8), and TDM availability (factor D: -0.8). Respondents from low-/middle-income countries were less likely to frequently/almost always use TDM compared to high-income countries (9.4% vs. 21.5%, p < 0.001).
UNASSIGNED: TDM use for antipsychotics was poor and associated with limited knowledge and insufficient availability.
摘要：
■这项调查评估了精神科居民/职业早期精神科医生对抗精神病药物治疗药物监测（TDM）效用的态度。
■先前制定的关于抗精神病药物治疗期间对TDM效用的态度的问卷在2022年1月1日至2023年12月31日期间由国家协调员按横截面分发。在线性回归分析中，使用TDM治疗除氯氮平以外的抗精神病药物的频率是主要结果，包括性,临床设置，案件量,以及探索性因素分析产生的因素。居民和早期职业精神病医生之间的比较，在门诊和门诊工作的受访者，以及低收入/中等收入和高收入国家。
■总之，1237名受访者完成了调查，37.9%从未使用过TDM抗精神病药。7个因素解释了41%的反应差异；其中6个因素与TDM使用频率相关(p<0.05)。因子负荷最高的项目包括TDM的临床益处（因子A和E：0.7），对患者对TDM的信念的负面期望（因素B：0.6-0.7），弱TDM科学证据(因子C：0.8)，和TDM可用性（系数D：-0.8）。与高收入国家相比，来自低收入/中等收入国家的受访者不太可能/几乎总是使用TDM（9.4%与21.5%,p<0.001)。
■抗精神病药的TDM使用较差，并且与知识有限和可用性不足有关。
■先前制定的关于抗精神病药物治疗期间对TDM效用的态度的问卷在2022年1月1日至2023年12月31日期间由国家协调员按横截面分发。在线性回归分析中，使用TDM治疗除氯氮平以外的抗精神病药物的频率是主要结果，包括性,临床设置，案件量,以及探索性因素分析产生的因素。居民和早期职业精神病医生之间的比较，在门诊和门诊工作的受访者，以及低收入/中等收入和高收入国家。
■总之，1237名受访者完成了调查，37.9%从未使用过TDM抗精神病药。7个因素解释了41%的反应差异；其中6个因素与TDM使用频率相关(p<0.05)。因子负荷最高的项目包括TDM的临床益处（因子A和E：0.7），对患者对TDM的信念的负面期望（因素B：0.6-0.7），弱TDM科学证据(因子C：0.8)，和TDM可用性（系数D：-0.8）。与高收入国家相比，来自低收入/中等收入国家的受访者不太可能/几乎总是使用TDM（9.4%与21.5%,p<0.001)。
■抗精神病药的TDM使用较差，并且与知识有限和可用性不足有关。
